secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0000950170-24-023509
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q4 revenue $14.7M (+53% YoY); guides FY2024 revenue $65-$68M
---------------------------------------------------------------------

- Full-year 2023 revenue $49.1M, +28% YoY; Lung Diagnostic test volume up 65%.
- Q4 gross margin 77% vs 66% a year ago; net loss improved 55% to $9.1M.
- FY2023 Adjusted EBITDA loss $32.7M, improved 24% YoY.
- Cash $26.3M at Dec 31, 2023; drew $10M second tranche from Perceptive term loan.
- FY2024 revenue guidance $65-$68M, representing 32%-39% YoY growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017024023509/0000950170-24-023509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017024023509/bdsx-20240301.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-023509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer